Comparison

Epithalon vs NAD+: Evidence-Based Comparison

Compare Epithalon and NAD+: dosing, mechanisms, safety profiles, and research evidence. Citation-backed comparison.

Overview

A comparison of Epithalon and NAD+ in longevity and mitochondrial research, including telomerase activation, NAD+ metabolism, and research protocol differences.

Compared compounds

Epithalon NAD+

Overview

Epithalon and NAD+ are both prominent in longevity-oriented research but operate through distinct biological pathways. Epithalon is a synthetic tetrapeptide bioregulator from Russian gerontology research, proposed to act through telomerase activation and gene expression regulation. NAD+ is an endogenous coenzyme essential to cellular energy metabolism, sirtuin activation, and DNA repair. Despite sharing a longevity research context, these are mechanistically different compounds with different evidence profiles and administration requirements.

Mechanism Comparison

Epithalon is studied primarily for its proposed role in telomerase activation, specifically increasing telomere length and slowing cellular senescence progression. It is also examined in the context of pineal gland regulation and neuroendocrine signaling. NAD+ research centers on its role as a substrate for sirtuins and PARP enzymes involved in DNA repair, mitochondrial biogenesis, and metabolic regulation. NAD+ concentrations decline with age, and supplementation studies examine whether restoring NAD+ levels can partially reverse age-related metabolic dysfunction.

Dosing and Protocol Comparison

Epithalon research protocols typically involve subcutaneous or intravenous injection courses of 10–20 mg total over a 10-day series, often repeated annually or semi-annually. NAD+ is studied in both oral supplementation forms (typically 250–1000 mg/day for precursors like NMN or NR) and direct subcutaneous injection (25–100 mg, 2–3 times per week). NAD+ administration routes have meaningfully different bioavailability profiles, and this is an active area of research debate.

Evidence Comparison

Epithalon's evidence base is concentrated in Russian gerontology literature, with limited independent Western replication. NAD+ and its precursors have a substantially larger and more geographically diverse evidence base, including multiple human clinical trials examining safety and pharmacokinetics. Both compounds are still considered research-stage for longevity applications, but NAD+ has a more mature translational evidence profile. Researchers interested in longevity-focused protocols often examine both compounds as addressing different aspects of cellular aging.

Frequently asked questions

Which is better, Epithalon or NAD+?

Epithalon and NAD+ are researched for different contexts, so the better choice depends on study goals, mechanism priorities, and protocol design.

Can you stack Epithalon and NAD+?

Some researchers evaluate Epithalon and NAD+ together, but combination design depends on evidence quality, safety considerations, and whether overlapping mechanisms are appropriate for the research question.